在急性晚期心力衰竭中,在多布胺输液下启动β-阻断剂:一个目标试验模拟与观察数据的目标试验
Yuichiro Mori1, Kosuke Inoue2,3, Hiroyuki Sato4
1Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, 54, Shogoin-Kawahara-cho, Sakyo-Ku, Kyoto-shi, Kyoto 6068507, Japan.
European heart journal open
|July 16, 2024
概括
在晚期心力衰竭中,在多布胺输液期间开始服用β-阻塞剂,在本研究中对生存结果没有显著影响. 这种早期β-阻断剂策略与延迟启动相比,没有改善或恶化整体存活率.
科学领域:
- 心脏病学 心脏病学
- 临床药理学 临床药理学
- 健康 结果 研究 研究 结果
背景情况:
- 患有晚期心力衰竭的患者通常需要多布胺输液.
- 标准实践建议在 dobutamine 断奶后开始服用β-阻断剂.
- 现实实践有时涉及在多布他胺输注期间启动β-阻断剂,临床含义不明.
研究的目的:
- 为了研究在 dobutamine 输注下早期启动β-阻断剂和生存结果之间的关联.
- 为了比较在多布他胺输注期间启动β-阻断剂的临床结果与断奶后的临床结果.
主要方法:
- 使用多中心住院患者数据库模拟实用随机对照试验 (RCT) 的观察性研究.
- 在多布胺 (早期策略) 下开始服用β-阻断剂的患者与未开始服用β-阻断剂的患者 (保守策略) 的 1:1匹配.
- 随访时间长达30天,主要结局是全因死亡. 方法包括克隆,审查和权重.
主要成果:
- 在780名匹配的患者中 (平均年龄为81岁),早期启动β-阻断剂的所有原因死亡的调整后风险比为1.11 (95% CI 0.75-1.64,P=0.59).
- 预计30天全因死亡率为早期启动策略的19.3%,保守策略的16.2%.
- 在策略确定的不同时间点中,结果保持一致.
结论:
- 在晚期心力衰竭中,在多布胺输液期间开始服用β阻塞剂与整体存活率的改善或恶化无关.
- 该研究发现,这种早期β-阻断剂启动策略没有显著的临床益处或危害.
- 研究结果表明,当前在 dobutamine 断奶后推迟β-阻断剂启动的做法,可能对生存结果来说并不严格必要.
更多相关视频
相关概念视频
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
430
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
430
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
662
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
662
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
733
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
733